Industry Leaders Select Resverlogix's RVX-208 Among Top 10 Most Promising Drugs

Calgary, Canada (ots/PRNewswire) - Resverlogix Corp's
("Resverlogix" or the "Company") (TSX:RVX) novel lead ApoA-I drug
candidate, RVX-208 has been selected as one of the top 10 most
promising cardiovascular disease (CVD) drugs available for strategic
partnering by an independent committee assembled by Windhover
Information, a leading provider of business information products and
services to senior executives in the pharmaceutical, biotechnology,
and medical device industries.

"We are honored to be part of this select group of top ten most
promising innovative drugs," stated Donald McCaffrey, President and
CEO of Resverlogix. "It again validates RVX-208 and our entire
NexVas(TM) PR franchise as an important new small molecule drug for
the largest market with unmet needs, atherosclerosis and
cardiovascular diseases. We are moving towards our next important
milestone, Phase 1b/2a, later this fall and continue to measure
safety, tolerability and key reverse cholesterol transport (RCT)
markers such as ApoA-I, pre-beta HDL, HDL and cholesterol efflux."

The selection committee was led by Marc Wortman, PhD,
contributing writer to Windhover's IN VIVO and Start Up
publications, and Michael Rice, Senior Consultant, and Ed Saltzman,
President of Defined Health, a leading business development strategy
consulting firm. Drawing on the analytic resources of these
organizations, the group evaluated hundreds of compounds currently in
development for the treatment of cardiovascular disease prior to
selecting RVX-208 among the top ten most attractive drug available
for partnering.

"Selected companies have been screened using a strict set of
judging criteria for the Top 10 award, and represent what our
committee considered the most attractive cardiovascular
opportunities the industry has to offer," stated Roger Longman,
Managing Director of Windhover Information. "Winners have met strict
criteria including: unmet medical need, market potential, diversity
of indications, strong science, multi-level partnering opportunities
(biotech and pharma), potential for new opportunities beyond initial
indications, history of the molecule and drug and be a strong
company."

"To have a highly regarded selection committee realize the
commercial potential for RVX-208 is important for us," stated
Kenneth Lebioda, Senior Vice President of Business and Corporate
Development at Resverlogix. "Atherosclerosis, the leading underlying
cause of cardiovascular death, represents the largest cost center to
health systems globally. Novel small molecules that enhance ApoA-I
production have a diverse number of patient groups that they can
help such as low HDL, acute coronary syndrome, diabetes, post
myocardial infarction and Alzheimer's. A novel drug that could help
these diseases will have a major positive impact on patients and
health systems alike. This is where RVX-208 offers an unrivalled
commercial opportunity for the life science industry," added Mr.
Lebioda.

As a selected company, Resverlogix has been invited to present
data on RVX-208 at Windhover's Therapeutic Area Partnerships
conference on November 3-5, 2008 in Philadelphia.

About Windhover

Windhover Information Inc., an Elsevier company, has led the
field in providing analysis of the healthcare industry to
decision-makers at all levels since the founding of its flagship
publication, IN VIVO, The Business & Medicine Report, in 1983.
Windhover provides its information and analysis in many formats,
including print, electronic databases, international conferences and
webinars. For more on the company's products and services, please
see http://www.windhover.com.

About Resverlogix Corp.

Resverlogix Corp. is a leading biotechnology company engaged in
the development of novel therapies for important global medical
markets with significant unmet needs. The NexVas(TM) program is the
Company's primary focus which is to develop novel small molecules
that enhance ApoA-I. These vital therapies address the grievous
burden of atherosclerosis and other important diseases such as acute
coronary syndrome, diabetes, Alzheimer's and other vascular
disorders. The Company's secondary focus is TGF-Beta Shield(TM), a
program that aims to address burgeoning grievous diseases, such as
cancer and fibrosis. Resverlogix Corp. trades on the Toronto Stock
Exchange (TSX:RVX). For further information please visit
http://www.resverlogix.com.

This news release may contain certain forward-looking statements
that reflect the current views and/or expectations of Resverlogix
Corp. with respect to its performance, business and future events.
Such statements are subject to a number of risks, uncertainties and
assumptions. Actual results and events may vary significantly. The
TSX Exchange does not accept responsibility for the adequacy or
accuracy of this news release.

For further information: Theresa Kennedy, VP, Corporate
Communications, Resverlogix Corp., Phone: +1-604-538-7072, Fax:
+1-403-256-8495, Email: Theresa@resverlogix.com; Sarah Zapotichny,
Manager, Investor Relations, Resverlogix Corp., Phone:
+1-403-254-9252, Fax: +1-403-256-8495, Email: Sarah@resverlogix.com,
Website: http://www.resverlogix.com (RVX.)

ots Originaltext: Resverlogix Corp.
Im Internet recherchierbar: http://www.presseportal.de

Contact:
For further information: Theresa Kennedy, VP, Corporate
Communications, Resverlogix Corp., Phone: +1-604-538-7072, Fax:
+1-403-256-8495, Email: Theresa@resverlogix.com; Sarah Zapotichny,
Manager, Investor Relations, Resverlogix Corp., Phone:
+1-403-254-9252, Fax: +1-403-256-8495, Email: Sarah@resverlogix.com